Shay Shemesh is Chief Dev. & Ops. Officer at Nuvectis Pharma, Inc. (NVCT). They have made 12 open-market trades across 1 company since 2022, most recently 2026-01-06.
CIK 0001896056
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
12 open-market purchases totalling $95K since 2022, never a sale. Across 12 scored buys the stock is up 15.0% at ninety days, and 10.7 points ahead of the S&P over the same stretch.
12 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NVCT | 1,793,068 | $33.1M |
Shares reported on the most recent Form 4, priced at the 2026-01-09 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 42% |
| Avg Move | -4.8% | -5.0% | +15.0% |
| Alpha | -5.9% | -3.9% | +10.7% |
| Scored | 12 | 12 | 12 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCT | BUY | 2024-05-10 | 2024-05-13 | $6.32 | $7K | +5.0% | +4.6% | -0.9% |
| NVCT | BUY | 2023-03-21 | 2023-03-22 | $11.99 | $5K | +4.6% | +10.2% | +42.9% |
| NVCT | BUY | 2023-03-15 | 2023-03-17 | $10.71 | $7K | -2.1% | +21.3% | +51.7% |
| NVCT | BUY | 2022-12-21 | 2022-12-22 | $7.65 | $4K | +1.5% | +2.2% | +66.0% |
| NVCT | BUY | 2022-11-16 | 2022-11-18 | $7.15 | $2K | +6.2% | +4.4% | +39.8% |
| NVCT | BUY | 2022-09-23 | 2022-09-27 | $7.87 | $2K | -5.4% | -4.9% | -1.2% |
| NVCT | BUY | 2022-09-02 | 2022-09-06 | $8.31 | $3K | -1.2% | -15.7% | -8.7% |
| NVCT | BUY | 2022-08-31 | 2022-09-02 | $8.07 | $24K | -2.2% | -11.6% | -7.1% |
| NVCT | BUY | 2022-05-20 | 2022-05-23 | $16.54 | $5K | -24.2% | -29.1% | -44.1% |
| NVCT | BUY | 2022-05-16 | 2022-05-18 | $19.44 | $5K | -20.5% | -42.0% | -51.5% |
| NVCT | BUY | 2022-05-12 | 2022-05-13 | $15.85 | $20K | -16.1% | -36.7% | -55.6% |
| NVCT | BUY | 2022-02-04 | 2022-02-08 | $3.41 | $10K | -3.0% | +36.8% | +149.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.